The European Medicines Agency (EMA) announced that it is still testing the AstraZeneca vaccine and will announce its findings tomorrow and Thursday after the official stated that there is a clear link between the vaccine and blood clotting cases.
Marco Cavaleri, who is in charge of the EMA vaccine strategy, said earlier Tuesday that it is clear that there is a link between thrombosis cases and AstraZeneca vaccination, but it is not clear what caused the reaction.
He added: “All in all, we will say there is a connection in a few hours, but we still have to determine how it happened.”
After Cavalieri’s statement, EMA said that the evaluation of AstraZeneca’s vaccine is still in progress and no conclusions have been reached. The results will be announced in the near future. In an interview with the Italian newspaper Is Messaggero, a spokesperson for the European agency declined to comment on Cavalieri’s claims.
EMA previously announced that the benefits of the AstraZeneca vaccine outweigh its risks, and the World Health Organization (WHO) is behind the British Swiss company’s vaccine.
AstraZeneca itself stated that its research shows that the use of vaccines does not increase the risk of blood clotting. EMA is investigating 44 rare reports of brain clots called cerebral venous sinus thrombosis (CVST). In the European Economic Community composed of the European Union, Iceland, Liechtenstein and Norway, 9.2 million people have been vaccinated with AstraZeneca.
In the United Kingdom, as of March 24, 30 vaccinators have been confirmed, of which 18 have died and 7 of them have died. Cavalieri said that EMA will say in its conclusion that there is a link between vaccines and thrombosis, but it is unlikely to announce this week which age group should avoid vaccines. During the test period, some countries/regions such as France, Germany and the Netherlands have suspended the use of this vaccine in the young population.